Is bremelanotide the same as PT-141? Yes — they are two names for the same melanocortin peptide. Compare Vyleesi, research vials, dosing and safety.
Yes — bremelanotide and PT-141 are the same molecule. PT-141 is the development code Palatin Technologies used during research, and bremelanotide is the generic (nonproprietary) name later assigned to that exact compound. The FDA-approved brand name is Vyleesi. So if you are asking whether bremelanotide is the same as PT-141, the answer is yes: these are two labels for one drug, not two different products.
The Short Answer: One Molecule, Three Names
Drug compounds collect multiple names as they move from the lab to the pharmacy. PT-141 was the internal code used in early studies, bremelanotide is the name used in medical literature and FDA labeling, and Vyleesi is the name printed on the prescription box.
| Name | What it is | Where you see it |
|---|---|---|
| Bremelanotide | Generic (nonproprietary) name | FDA labels, prescribing information, medical journals |
| Vyleesi | Brand name | US pharmacies and prescription product listings |
| PT-141 | Research and development code | Early studies and research chemical suppliers |
| Bremelanotide acetate | Salt form of the same peptide | Laboratory vials and catalogs |
Why the compound has two names
Pharmaceutical companies assign internal codes so researchers can track a candidate molecule before it has an official name. PT-141 followed that path at Palatin Technologies. Once the compound advanced toward approval, the generic name bremelanotide was assigned.
The two names do not describe different strengths, salts, or modified versions of the peptide. Sellers that list them as separate products are usually describing the same sequence under two labels.
What Bremelanotide (PT-141) Is Approved For
Vyleesi is FDA-approved to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is a subcutaneous injection rather than a pill, and it is used on demand instead of daily.
- Dose: 1.75 mg injected under the skin of the abdomen or thigh.
- Timing: at least 45 minutes before anticipated sexual activity.
- Limits: no more than one dose in 24 hours and no more than eight doses per month.
- Population: premenopausal women only; it is not approved for men or for postmenopausal women.
Bremelanotide is a melanocortin receptor agonist that acts on MC4R in the central nervous system. It is not a hormone, and it does not work like PDE5 inhibitors such as sildenafil. People who search what is pt-141 usually land on the same answer: it is the research code for the compound now sold as Vyleesi.
Prescription Vyleesi vs. Research-Grade PT-141 Vials
The names overlap, but the products do not. One is a regulated medicine, and the other is a laboratory material sold for research purposes.
| Factor | Vyleesi (prescription) | Research-grade PT-141 |
|---|---|---|
| Regulatory status | FDA-approved | Not FDA-approved |
| Intended use | HSDD in premenopausal women | Laboratory research only; not for human use |
| Typical form | Single-use autoinjector, 1.75 mg | Lyophilized powder in a vial |
| Quality oversight | cGMP manufacturing with batch testing | Variable; certificates of analysis may be incomplete or unverified |
| Dosing guidance | Defined by the FDA label | None; sold with a not-for-human-consumption disclaimer |
Vials labeled pt-141 bremelanotide injection 20mg vial are research products, and the 20 mg figure describes the total peptide in the vial rather than a single dose. That amount is roughly eleven times the 1.75 mg prescription dose, which is one reason self-dosing from a research vial is unsafe.
Side Effects, Dosing, and Safety Considerations
In clinical trials, the most frequently reported side effects of bremelanotide were nausea, flushing, headache, and injection site reactions. Vomiting and short-lived increases in blood pressure were also reported.
Bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. Repeated use can also cause focal hyperpigmentation, a darkening of the gums, face, or other skin areas.
Anyone considering bremelanotide should review their blood pressure history and current medications with a healthcare professional before use. Research-grade peptides bypass that oversight entirely.
A related question — is bac water the same as saline — matters for anyone handling lyophilized vials, because the two liquids are not interchangeable and the wrong diluent can affect stability and sterility.
Other Names That Get Confused With Bremelanotide
Naming confusion is common across peptides and prescription drugs. Searches like is cjc 1295 the same as ipamorelin appear for the same reason: related compounds get discussed together, and their names start to blur.
In the metabolic drug space, is tirzepatide the same as ozempic is asked just as often, even though those products contain different active ingredients and carry different approvals.
The practical habit is simple. Check the active ingredient on the label rather than the nickname in the marketing copy. If the ingredient name matches, the product is the same molecule; if it does not, similar branding does not make two compounds equivalent.
Key Takeaways
- Bremelanotide and PT-141 are the same molecule; PT-141 is the research code and bremelanotide is the generic name.
- Vyleesi is the FDA-approved brand name of bremelanotide, approved for HSDD in premenopausal women.
- Bremelanotide is not FDA-approved for use in men.
- Research-grade PT-141 is not FDA-approved and is not intended for human use.
- Nausea, flushing, headache, and blood pressure changes are the main safety concerns, and a healthcare professional should be involved in any decision to use it.
Frequently Asked Questions
Is bremelanotide the same as PT-141?
Yes. PT-141 was the development code Palatin Technologies used for the compound, and bremelanotide is the generic name assigned to that same molecule. Vyleesi is the FDA-approved brand name for it, so all three names refer to one drug.
Is PT-141 the same as Viagra?
No. PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on the central nervous system, while sildenafil and other ED medications are PDE5 inhibitors that affect blood flow. They are different drug classes with different mechanisms, side effects, and approved uses.
Is bremelanotide approved for men?
No. Vyleesi is FDA-approved only for premenopausal women with hypoactive sexual desire disorder. It has been studied in men, but it does not have FDA approval for male use, and research-grade PT-141 sold online is not approved for human use by anyone.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.